Clinical Trial

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

Study acronym: AVENTIL
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase 1, dose-escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with avelumab in patients with advanced solid tumors refractory to or progressing after anti-PD(L)1.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-02-01; most recent amendment 2025-08-04.
Status change: Recruiting → Active, Not Recruiting 2025-08-04
Status change: Not Yet Recruiting → Recruiting 2022-07-12
Trial Details
NCT Number NCT05222932
Lead Sponsor TILT Biotherapeutics Ltd.
Conditions Melanoma, Head and Neck Squamous Cell Carcinoma
Enrollment 15 participants
Start Date 2023-03-08
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-07